AI assistant
BIOTRON LIMITED — Capital/Financing Update 2025
Apr 7, 2025
64528_rns_2025-04-07_947cdb4e-5176-4ea6-b4fb-434a33a36171.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [227 x 35] intentionally omitted <==
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: [email protected] Website: www.biotron.com.au
8 April 2025
The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000
Dear Madam
Successful Completion of the Entitlement Offer
Biotron Limited (ASX: BIT, Biotron or the Company ) is pleased to announce that the renounceable rights issue announced on 28 February 2025 has closed, raising $1,274,589 (before costs). The Company will issue 424,863,077 new fully paid ordinary shares ( Shares ).
The Company would like to thank all shareholders for their support of the rights issue, particularly in these difficult times, and would like to welcome new investors to the register.
It is noted that the Company’s Directors and management took up their entitlements in full, demonstrating strong commitment to the Company and confidence in its future.
The final allocations are set out below:
| Funds Raised | Shares Issued | ||
|---|---|---|---|
| Rights taken up | $668,336 | 222,778,637 | |
| Shortfall | $606,253 | 202,084,440 | |
| Total | $1,274,589 | 424,863,077 |
As set out in the Prospectus for the offer, the net proceeds will enable the Company to continue commercialisation activities foused on achieving strategic partnership(s) for its portfolio of antiviral programs including its lead asset BIT225, expand its promising early stage Hepatitis B virus program, and support ongoing administration and operational costs.
Mahe Capital Pty Ltd acted as Lead Manager and Underwriter to the rights issue.
The new securities will be issued on Tuesday, 8 April 2025, in accordance with the timetable in the prospectus. The Directors and the Lead Manager reserve the right to place any shortfall shares at their discretion within 3 months of the closing date.
This Announcement has been approved for release by the Board of Directors.
Yours sincerely
==> picture [92 x 60] intentionally omitted <==
Peter J. Nightingale Company Secretary
pjn12585
Enquiries: Dr Michelle Miller Managing Director Biotron Limited +61-(0)412313329
Rudi Michelson Monsoon Communications +61-3 9620 3333